Amarin suffers another blow at the hands of the FDA

John Carroll

Already suffering from an expert panel rejection for an expanded label on its cholesterol drug Vascepa, was subjected to drubbing on Wall Street after the FDA formally withdrew its Special Protocol Assessment agreement on a study of the treatment.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS